Pesquisar
Abcellera Biologics Inc
ABCLAdicionar à lista de desejos
12.310USD
-0.340-2.69%
Fechamento 09-23 16:00（ET）
3.76BValor de mercado
PerdaP/L TTM
Após o expediente 17:00 (ET)12.340USD+0.025+0.20%
Após o expediente 17:00 (ET)Sobre o Abcellera Biologics Inc Empresa
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Abcellera Biologics Inc Perfil
Código da empresaABCL
Nome da EmpresaAbcellera Biologics Inc
Data de listagemDec 11, 2020
CEOHansen (Carl L.G)
Número de funcionários596
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 11
Endereço150 W 4Th Avenue
CidadeVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV5Y 1G6
Telefone16045599005
Sitehttps://www.abcellera.com/
Código da empresaABCL
Data de listagemDec 11, 2020
CEOHansen (Carl L.G)
Executivos da empresa Abcellera Biologics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
9.61M
--
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
613.76K
+6.06%
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
613.76K
+6.06%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden, Ph.D.
Dr. Michael R. Hayden, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Stephen R. Quake
Dr. Stephen R. Quake
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
9.61M
--
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
613.76K
+6.06%
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
613.76K
+6.06%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Abcellera Biologics Inc?
Os cinco principais acionistas de Abcellera Biologics Inc são: Dr. Veronique Lecault, Ph.D.
Quantas instituições possuem ações da Abcellera Biologics Inc (ABCL)?
Em 2026Q1, 323 instituições possuíam ações da Abcellera Biologics Inc, com valor de mercado aproximado de 131.69M, representando 43.14% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -19217264.00.
Qual é a maior fonte de receita da Abcellera Biologics Inc?
Em 2026Q1, o segmento de negócios Licensing revenue gerou a maior receita para Abcellera Biologics Inc, totalizando 46.92M e representando 62.45% da receita total.